Transcell Biologics Sponsors MCADDI 2026, Advancing Human-Relevant Drug Discovery Through DART

Hyderabad | 28 October 2026 Transcell Biologics participated as a sponsor at MCADDI 2026 – Medicinal Chemistry, Drug Discovery & Development India, hosted at the University of Hyderabad. The prestigious six-day program, held from 25–30 October 2026, brought together leading scientists, pharmaceutical industry professionals, academic researchers and drug discovery experts to explore advances across the drug development continuum. Representing its commitment to accelerating the transition toward human-relevant preclinical science, Transcell Biologics showcased its flagship innovation, DART – Digital Animal Replacement Technology. DART integrates human microphysiological systems, advanced biological characterization and AI-enabled analytical frameworks to investigate drug efficacy, safety pharmacology, toxicity, potency, immunogenicity and translational performance. Bridging the Gap Between Molecular Discovery and Human Biological Response While medicinal chemistry and computational drug discovery continue to generate increasingly sophisticated therapeutic candidates, predicting their behavior in human biological systems remains a major challenge. DART seeks to address this translational gap by providing biologically relevant experimental evidence that complements molecular and computational approaches, supports better-informed development decisions and advances the adoption of New Approach Methodologies (NAMs). Transcell Biologics’ sponsorship reflects its commitment to strengthening India’s drug discovery ecosystem through industry-academia engagement, human-centric innovation and responsible integration of artificial intelligence into pharmaceutical R&D. The company extends its appreciation to the Federation of Asian Biotech Associations (FABA) and the organizing institutions for facilitating scientific exchange and collaboration across the pharmaceutical innovation ecosystem. Transcell Biologics believes the next competitive advantage in drug development will come from understanding human biology earlier—not merely discovering molecules faster. DART – Human Biology Before Human Trials.